Zynex Announces Open Oximetry Project Membership
Zynex Announces Open Oximetry Project Membership
ENGLEWOOD, Colo., Dec. 3, 2024 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI) ("Zynex", "ZMS", "we" or the "Company"), an innovative medical technology company specializing in the manufacture and sale of noninvasive medical devices for pain management, rehabilitation, and patient monitoring, today announced its membership in the Collaborative Community of the independently led Open Oximetry Project as an industry member.
ENGLEWOOD,科羅拉多州,2024年12月3日/ PRNewswire/ -- zynex,Inc.(NASDAQ: ZYXI)("Zynex","ZMS","我們"或"公司"),一家專注於生產和銷售無創醫療設備用於疼痛管理、康復和患者監測的創新醫療技術公司,今天宣佈成爲獨立領導的開放血氧項目協作社區的行業成員。
The Open Oximetry Project, an initiative led by the University of California, San Francisco's Center for Health Equity in Surgery and Anesthesia, is dedicated to improving the safety and accuracy of pulse oximeters in all populations. Through its Collaborative Community comprised of global stakeholders, including academic researchers, regulatory bodies, industry partners, and healthcare providers, the project fosters accelerated progress and the sharing of knowledge in this critical area.
開放血氧項目是由加利福尼亞大學舊金山分校衛生平等外科與麻醉中心領導的一項倡議,致力於改善所有人群脈搏血氧儀的安全性和準確性。通過其由全球利益相關者組成的協作社區,包括學術研究人員、監管機構、行業合作伙伴和醫療保健提供者,該項目促進了這一關鍵領域的加速進展和知識共享。
In alignment with these objectives, Zynex Monitoring Solutions (ZMS) is developing the NiCO pulse oximeter which utilizes laser technology to accurately measure blood oxygenation levels, as opposed to current LED technology, which only estimates oxygenation levels. LED pulse oximeters have been shown to inaccurately measure oxygen levels in several populations, most predominantly on individuals with darker skin pigmentation.
爲了實現這些目標,zynex監測解決方案(ZMS)正在開發利用激光技術準確測量血氧水平的NiCO脈搏血氧儀,而不是目前僅估算氧合水平的LED技術。已經證明,LED脈搏血氧儀在一些人群中(主要是皮膚色素較深的個體)會出現測量氧氣水平不準確的情況。
ZMS is currently in the final stages of its verification studies for NiCO, which are required before submitting for full 510(k) clearance by the FDA. Zynex Monitoring Solutions' NiCO product line is a strategic investment for Zynex to enter the multi-billion dollar pulse oximetry market with entirely new pulse oximetry technology. The Company is confident that the clinical value of NiCO's unparalleled precision, accuracy, and safety will provide the right entry into this market space.
ZMS目前正在進行NiCO的驗證研究的最後階段,這些研究是在向FDA提交完整510(k)清關之前必不可少的。zynex監測解決方案的NiCO產品線是zynex進入數十億美元脈搏血氧儀市場的戰略投資,採用全新的脈搏血氧技術。公司相信,NiCO無與倫比的精確性、準確性和安全性的臨床價值將爲其進入這一市場提供正確途徑。
"Open Oximetry provides a vital independent service to the public, raising awareness of the shortfalls and performance levels of current oximetry products. This is an important first step in improving patient care and pushing for technology advancements that resolve these well-published and well-recognized monitoring deficiencies." said Donald Gregg, President of Zynex Monitoring Solutions. "We are pleased to join the Collaborative Community of the Open Oximetry Project to contribute to a better understanding of the clinical performance of current LED pulse oximetry and to work toward better healthcare through safer and more inclusive medical monitoring solutions."
"開放血氧向公衆提供了一項重要的獨立服務,提高了當前血氧產品的缺點和性能水平的認識。這是改善患者護理、推動解決這些被廣泛報道和公認的監測缺陷的技術進步的重要第一步。"zynex監測解決方案總裁唐納德格雷格表示。"我們很高興加入開放血氧項目的協作社區,爲更好地了解當前LED脈搏血氧的臨床性能,努力創造更安全、更包容的醫療監測解決方案做出貢獻。"
About Open Oximetry
關於開放式脈搏氧監測
Founded at UCSF's Center for Health Equity in Surgery and Anesthesia (CHESA) and the UCSF Hypoxia Lab, the Open Oximetry project was created to improve the safety and precision of pulse oximeters in all populations as these devices have been found to be less accurate in people with darker skin tone. The Open Oximetry Project has organically grown into a hub for bringing together oximetry experts, engineers, academic researchers, clinicians, community members, manufacturers, and regulatory bodies from all geographies and backgrounds. We hope to continue to invite and hold space for diverse voices to work in partnership to tackle these issues.
開放式脈搏氧監測項目成立於UCSF衛生公平外科與麻醉(CHESA)中心和UCSF缺氧實驗室,旨在提高所有族群的脈搏氧儀的安全性和精確性,因爲已發現這些設備在膚色較深的人群中精度較低。開放式脈搏氧監測項目已經逐漸發展成爲一個聚集了脈搏氧監測專家、工程師、學術研究人員、臨床醫生、社區成員、製造商和監管機構來自各地域和背景的樞紐。我們希望繼續邀請和爲不同聲音留下空間,共同合作解決這些問題。
About Zynex, Inc.
關於Zynex,Inc。
Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: .
zynex成立於1996年,開發、製造、營銷和銷售用於疼痛管理和康復以及非侵入性流體、敗血症和基於激光的脈搏血氧監測系統,用於醫院。欲知更多信息,請訪問:。
Safe Harbor Statement
Safe Harbor聲明
This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995.
本發佈包含了根據1995年美國《私人證券訴訟改革法》安全港規定的前瞻性聲明。
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our products on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2023 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K.
前瞻性聲明既非歷史事實,也非對未來業績的保證。相反,它們僅基於我們當前對業務未來、未來計劃和策略、預期事件和趨勢、經濟以及其他未來情況的信念、期望和假設。由於前瞻性聲明涉及未來,因此受到固有的不確定性、風險和難以預測的環境變化的影響,其中許多是我們無法控制的。我們的實際結果和財務狀況可能與前瞻性聲明中所示有實質性差異。因此,您不應依賴於其中任何前瞻性聲明。公司對前瞻性聲明的完整性或在投影中的實現可能性,以及其派生假設的準確性和完整性,不作明示或暗示的陳述或保證。可能導致實際結果與前瞻性聲明實質性不符的因素包括,但不限於,需要爲新產品獲得CE標記,醫生和醫院接受新產品以及現有產品,具有更多財務資源的較大競爭對手,需要跟上技術變化,我們依賴來自醫療保險公司的對產品的報銷,我們依賴第三方製造商按時生產符合規格的產品,實施我們的銷售策略,包括強大的直銷團隊,COVID-19對全球經濟的影響以及在我們向美國證券交易委員會提交的備查文件中描述的其他風險,包括但不限於,截至2023年12月31日年度報告10-k,以及我們的季度報告10-Q和8-k現報告。
Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
我們在本公告中所發表的任何前瞻性聲明僅基於目前我們所掌握的信息,並僅於發表聲明之日起生效。我們不承諾公開更新任何前瞻性聲明,無論是書面的還是口頭的,這些聲明可能隨時因新信息、未來發展或其他原因而發生變化。
Investor Relations Contact:
Brian Prenoveau, CFA
MZ Group – MZ North America
[email protected]
+561 489 5315
投資者關係聯繫人:
Brian Prenoveau,特許金融分析師
MZ Group – MZ North America
[email protected]
+561 489 5315
SOURCE Zynex, Inc.
消息來源:zynex公司